ARS Pharmaceuticals Director Peter Thompson Granted 30,000 Stock Options

Peter A. Thompson, a director of ARS Pharmaceuticals, Inc. (SPRY), was granted 30,000 stock options on June 24, 2026. The options have an exercise price of $10.54 per share and expire on June 23, 2036. The options will vest in full on the earlier of June 24, 2027 or the date of the company's 2027 annual meeting of stockholders. According to footnotes, Thompson is obligated to transfer any securities issued under these stock options, or their economic benefits, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will then provide them to OrbiMed Private Investments VI, LP. This arrangement indicates the options are part of a compensation arrangement tied to Thompson's role as a director representing OrbiMed's interests. The filing was signed by an attorney-in-fact on June 26, 2026.